Partner & CSO
B2S Life Sciences
Indianapolis, Indiana
Dr. Bowsher’s career in BioPharma and CRO industries has spanned 4½ decades. He is a recognized thought-leader in the areas of bioanalytical methods development for regulatory-compliant bioanalysis, ADME and immunogenicity assessments of biotherapeutics. He received his M.S. and Ph.D. degrees in Biochemistry & Molecular Biology at IN University School of Medicine (Indianapolis, IN). Currently, he is Partner and CSO at B2S Life Sciences™ (www.B2SLifeSciences.com), a Biotherapeutic Enablement laboratory in Franklin, IN specializing in the generation and life-cycle management of custom biological reagents, assay development, ADME to support biotherapeutic drug development and data analytics for PK/TK and immunogenicity. In 2003, Dr. Bowsher retired after more than 30 years at the Lilly Research Laboratories where he led research groups responsible for supporting regulated bioanalysis of biotherapeutics and conventional small molecule drugs. Since 1980, he has published >250 research papers, monographs, and abstracts, has four patents, 75 invited lectures, been a consultant to >150 global companies and has served on several scientific advisory boards. In 2004, Dr. Bowsher was elected as an AAPS Fellow. In 2008, he was given an AAPS Presidential citation for his efforts to establish educational training programs. In 2011, Dr. Bowsher received the AAPS BIOTEC Section distinguished service award.
Disclosure information not submitted.
Insights into Non-Bridging Assay Designs for Detection of Anti-Drug Antibodies
Tuesday, July 15, 2025
10:05 AM - 10:35 AM ET
Beyond the Analysis: Immunogenicity and Beyond: Panel Discussion
Tuesday, July 15, 2025
11:05 AM - 11:55 AM ET